Summary
AbbVie will present 21 abstracts at EHA 2026 spanning multiple myeloma, DLBCL, follicular lymphoma, CLL, AML, and AL amyloidosis. The most important readout is etentamig (ABBV-383) in patients previously exposed to BCMA-directed therapies, a setting with significant unmet need and no clear standard of care.
What Happened
Key presentations include MONVISO Arm B data for etentamig in relapsed/refractory multiple myeloma after BCMA therapy, updated epcoritamab datasets in DLBCL and follicular lymphoma, venetoclax biomarker analyses in CLL, and pivekimab sunirine updates in AML. The congress takes place June 11–14 in Stockholm.
Deep Analysis
The most strategically important asset is etentamig. Nearly every major myeloma company is now trying to solve the post-BCMA problem. Patients progressing after BCMA CAR-T or BCMA bispecific therapy have limited options and represent the next major commercial battleground in myeloma. Etentamig targets FcRH5, giving AbbVie an orthogonal antigen strategy that avoids direct dependence on BCMA expression. If activity remains strong after BCMA exposure, AbbVie gains a differentiated position in one of the fastest-growing segments of the myeloma treatment algorithm. Epcoritamab data remain important, but the market increasingly understands the CD20×CD3 bispecific story. Etentamig is the asset with the greatest potential to alter competitive positioning.
Competitive Displacement
Positive MONVISO data would directly pressure J&J’s talquetamab and BMS’s mezigdomide in the post-BCMA setting. The emerging question for 2026 is which mechanism becomes the preferred salvage strategy after BCMA failure: FcRH5 targeting, GPRC5D targeting, or CELMoD-based therapy.
Company / Product Background
Etentamig (ABBV-383) is an FcRH5×CD3 bispecific antibody designed to redirect T cells toward myeloma cells. FcRH5 is broadly expressed across malignant plasma cells and represents one of the leading non-BCMA targets in multiple myeloma development.
Signal Extraction
- Post-BCMA myeloma remains a major unmet need
• FcRH5 emerging as a key next-generation target
• AbbVie building depth across multiple hematologic franchises
• EHA data may reshape salvage-treatment sequencing
Insilens Take
The value of this EHA package is not the number of abstracts but the positioning of etentamig. If AbbVie demonstrates durable efficacy after BCMA exposure, the company becomes a serious contender in the next phase of myeloma evolution. The post-BCMA market may ultimately prove larger and more strategically important than earlier-line opportunities because every successful BCMA therapy creates future post-BCMA patients.
